Australian, youngest yet diagnosed, and 5th only reported case of ARPC1B deficiency.
Investigations showed defective neutrophil chemotaxis and random migration, reduced Natural Killer cell cytotoxicity, decreased naïve T-cells, variable thrombocytopenia, eosinophilia, and raised IgA and IgE. Whole exome sequencing showed her to be homozygote for an exon 2 splice site mutation in ARPC1B (c.64+2T>A) which is predicted to cause loss of gene function. Western blot analysis showed low expression of the ARPC1B protein.
ARPC1B is a regulatory subunit of the actin-related protein 2/3 complex critical for F-actin polymerisation in haemopoetic cells. Deficiency of ARPC1B results in defective actin polymerisation and a combined immunodeficiency similar but distinct to WAS. Hereditary Angioedema (HAE) is a rare condition, affecting approx. 1 in 50 000, and knowledge within the general medical community (i.e. outside Immunology clinics) is low. To support patients & clinics, the ASCIA HAE Positioning Paper (2017) recommends that each HAE sufferer has a HAE Action Plan highlighting when to initiate home based selfadministrated medication and when to escalate to ED.
In October 2016, the HAE treatment paradigm changed significantly in Australia with the NBA funding of C1-INH concentrate. However, the question remained regarding feasibility regarding home based preparation and infusion.
Aesir Health (independent provider with 13+ years' experience educating patients on self-administered sub-cutaneous injectables) commissioned by CSL Behring, designed, built and is managing the Berinert NurseCare Educational Program (initiated in Feb 2017) . This national program has objectives to ensure concordance with BERINERT ® (Human C1-Esterase Inhibitor) prescribing on several levels including:
• competence in reconstitution • accurate vein identification, site rotation & aseptic venepuncture • correct administration, post procedure care and documentation • clarity of patient's HAE Action Plan including customisation with home circumstances and support networks Currently, 16 patients are enrolled, requiring an average of 2.5 visits per patient and 4.8 total hrs per education per patient. Some attributes facilitating uptake and acceptance to home-infusion include having direct family/carer support networks, experiencing recent HAE attacks, poor experience at ED. Learning is complimented by using novel training apparatus plus the opportunity to prepare & administer BERINERT.
These initial findings suggest that home based infusion is feasible and further investigation into the elements which patients find challenging or supportive is warranted. This model has adopted a collaborative approach with the support of CSL product advisors and educators, treating clinicians, the BH transfusion services clinical nurse specialists, existing BH day infusion and pharmacy services.
Patient education modules, education brochures, SCIg specific care plans and processes have been developed to support the model of care.
The transition from IVIg to SCIg is occurring with initial treatment and education in the HITH clinic, followed by treatment and education in the home setting, Dependent on patient competency and confidence it is envisaged that most patients will transition to self-management within 4-6 weeks. HITH will provide ongoing support and education with planned reviews and facilitation of product ordering and supply and provision of consumables.
Results:
The program is currently in the early stages of implementation. A questionnaire is being used to measure patient experience and satisfaction. An evaluation of the program based on number of patient enrolments, reduction in health service costs and treating clinician engagement and satisfaction of treatment efficacy will be utilised to support this approach to care.
Conclusion:
The HITH approach to the implementation of a SCIg program is an important initiative providing patients with an alternative and self-management care option. Introduction: Peripheral ulcerative keratitis (PUK) can be a secondary manifestation of systemic autoimmune diseases, most commonly Rheumatoid arthritis (RA) and Granulomatosis Polyangiitis GPA). PUK can precede systemic symptoms and its presence may herald sight threatening if not life threatening disease. Mooren's ulcer is a rare form of idiopathic PUK, whose aetiology includes autoimmunity and loss of tolerance to components within the corneal stroma. Whilst biologic agents have been successful in treating systemic disease and PUK in RA and GPA, their role in treating PUK in the absence of systemic autoimmune diseases remains less clear.
Case report: We present the case of a 16-year-old female who developed sudden onset bilateral painful ulcerative keratitis. She was diagnosed with Mooren's ulcer in absence of evidence of systemic autoimmune disease on clinical examination or autoimmune serology.
Despite topical and systemic steroid therapy, she developed 'corneal melt' requiring an urgent tectonic corneal graft and with IV methylprednisolone, oral prednisolone and mycophenolate mofetil to stabilise disease. Her disease course was characterised by fluctuating visual acuity and progressive corneal thinning with recurrent disease within the corneal graft and progression toward re-perforation despite ongoing immunosuppression. She was given a trial of rituximab given the aggressive and refractory nature of 
